翰森制药HS-10,568注射液新药上市申请获中国药监局受理用于治疗成人慢性肾病继发性甲状旁腺功能亢进

美股速递06-10

翰森制药集团宣布，其创新药物HS-10,568注射液用于治疗成人慢性肾脏病患者继发性甲状旁腺功能亢进的新药上市申请，已获得中国国家药品监督管理局的正式受理。此举标志着该药物在中国商业化进程中的关键一步，有望为相关患者群体提供新的治疗选择。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1102690614?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-10 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102690614","market":"us","top_or_hot":-1,"title":"翰森制药HS-10,568注射液新药上市申请获中国药监局受理 用于治疗成人慢性肾病继发性甲状旁腺功能亢进","media":"美股速递","content":"<p>翰森制药集团宣布，其创新药物HS-10,568注射液用于治疗成人慢性肾脏病患者继发性甲状旁腺功能亢进的新药上市申请，已获得中国国家药品监督管理局的正式受理。此举标志着该药物在中国商业化进程中的关键一步，有望为相关患者群体提供新的治疗选择。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰森制药HS-10,568注射液新药上市申请获中国药监局受理 用于治疗成人慢性肾病继发性甲状旁腺功能亢进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰森制药HS-10,568注射液新药上市申请获中国药监局受理 用于治疗成人慢性肾病继发性甲状旁腺功能亢进\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-10 18:42 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>翰森制药集团宣布，其创新药物HS-10,568注射液用于治疗成人慢性肾脏病患者继发性甲状旁腺功能亢进的新药上市申请，已获得中国国家药品监督管理局的正式受理。此举标志着该药物在中国商业化进程中的关键一步，有望为相关患者群体提供新的治疗选择。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1102690614","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102690614","pubTimestamp":1781088138,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"翰森制药集团宣布，其创新药物HS-10,568注射液用于治疗成人慢性肾脏病患者继发性甲状旁腺功能亢进的新药上市申请，已获得中国国家药品监督管理局的正式受理。此举标志着该药物在中国商业化进程中的关键一步，有望为相关患者群体提供新的治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","BK1589":"北水核心资产","03692":"翰森制药"},"translate_title":"Hansen Pharmaceutical's new drug marketing application for HS-10,568 injection was accepted by the China Food and Drug Administration for the treatment of hyperparathyroidism secondary to chronic kidney disease in adults","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"翰森制药集团宣布，其创新药物HS-10,568注射液用于治疗成人慢性肾脏病患者继发性甲状旁腺功能亢进的新药上市申请，已获得中国国家药品监督管理局的正式受理。此举标志着该药物在中国商业化进程中的关键一步，有望为相关患者群体提供新的治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102690614","isCrawlerRequest":true}

翰森制药HS-10,568注射液新药上市申请获中国药监局受理 用于治疗成人慢性肾病继发性甲状旁腺功能亢进

精彩评论

翰森制药HS-10,568注射液新药上市申请获中国药监局受理用于治疗成人慢性肾病继发性甲状旁腺功能亢进